Lupus

Provention Bio Announces Senior Leadership Addition

Retrieved on: 
Monday, September 19, 2022

"Sarah joins us at a key juncture, as we work to scale and grow Provention Bio while staying relentlessly focused on our purpose to intercept and prevent life-threatening autoimmune diseases," stated Ashleigh Palmer, Co-Founder and Chief Executive Officer, Provention Bio.

Key Points: 
  • "Sarah joins us at a key juncture, as we work to scale and grow Provention Bio while staying relentlessly focused on our purpose to intercept and prevent life-threatening autoimmune diseases," stated Ashleigh Palmer, Co-Founder and Chief Executive Officer, Provention Bio.
  • Sarah joins Provention Bio as a highly-accomplished human resources leader with extensive experience building and growing impactful organizations.
  • The stock option is subject to the terms of the Provention Bio, Inc. 2020 Inducement Plan, as amended.
  • Provention Bio, Inc. uses its website, www.proventionbio.com , as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D.

Walk to End Lupus Now® Brings Communities Together to Help End Lupus

Retrieved on: 
Wednesday, September 14, 2022

Each walk event unites communities for one common purpose to take steps together to help end lupus.

Key Points: 
  • Each walk event unites communities for one common purpose to take steps together to help end lupus.
  • The Lupus Foundation of America's Walk to End Lupus Now events represent the largest lupus walk program in the world.
  • "As more people come together to participate in the Walk to End Lupus Now, we are able to raise more money to advance lupus research and support people with lupus," shared Petra Tchouante, participating in her ninth Walk to End Lupus Now event.
  • "Walk to End Lupus Now events are an opportunity for us to connect directly with those impacted by the disease and make a difference in the fight to end lupus.

Alpine Immune Sciences to Highlight Clinical Updates on Autoimmune and Immuno-Oncology Programs at Inaugural R&D Day

Retrieved on: 
Monday, September 12, 2022

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced clinical updates from two wholly owned programs, ALPN-303 and davoceticept.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced clinical updates from two wholly owned programs, ALPN-303 and davoceticept.
  • Davoceticept, our lead Immuno-oncology program, continues to show encouraging signs of meaningful clinical activity with an acceptable safety profile.
  • Alpine Immune Sciences is committed to leading a new wave of immune therapeutics.
  • NEON-1, NEON-2, "Synergy," RUBY and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.

Six New Member Companies Join the International Consortium for Innovation and Quality in Pharmaceutical Development

Retrieved on: 
Monday, September 12, 2022

WASHINGTON, Sept. 12, 2022 /PRNewswire-PRWeb/ -- The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium) announced the joining of six (6) new member companies at its recent Board of Directors meeting. The new members are Novo Nordisk, The Bill and Melinda Gates Medical Research Institute, Relay Therapeutics, Xencor, CSL Behring, and Idorsia. This brings the IQ Consortium membership to 44 companies.

Key Points: 
  • The IQ Consortium continues to grow and advance innovative solutions in pharmaceutical development through precompetitive collaboration.
  • WASHINGTON, Sept. 12, 2022 /PRNewswire-PRWeb/ -- The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium) announced the joining of six (6) new member companies at its recent Board of Directors meeting.
  • Margaret Faul , the consortium Chair, said that "it is exciting to welcome new members to the IQ Consortium.
  • The IQ Consortium is proud to have these innovative companies join the consortium and looks forward to further collaboration in the pursuit of pharmaceutical development, technical innovation, and continued service to patients.

Nimbus Therapeutics Closes $125M Private Financing to Advance Clinical Programs in Autoimmune Diseases and Oncology

Retrieved on: 
Monday, September 12, 2022

Nimbus Therapeutics , a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today announced the closing of a $125 million private financing.

Key Points: 
  • Nimbus Therapeutics , a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today announced the closing of a $125 million private financing.
  • Were proud to lead this financing round to advance Nimbus exciting pipeline of clinical and preclinical candidates, said Nikola Trbovic, Ph.D., Partner at SV Health Investors.
  • In addition to this financing, Nimbus has recently appointed Gorjan Hrustanovic, Ph.D., Managing Director of BVF Partners, L.P., to its Board of Directors.
  • Nimbus has designed, discovered and developed a diverse portfolio of clinical and preclinical programs focused on inflammatory and autoimmune disorders, cancer and metabolic diseases, including three internally discovered compounds that have advanced into clinical trials.

Provention Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Tuesday, September 6, 2022

RED BANK, N.J., Sept. 6, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate virtually in a corporate presentation at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12th at 7:00am EST.

Key Points: 
  • RED BANK, N.J., Sept. 6, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate virtually in a corporate presentation at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12th at 7:00am EST.
  • The presentation will be webcast live and can be accessed by visiting the Events and Webcasts section of the Company's website: http://investors.proventionbio.com/events .
  • Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases.
  • Provention Bio, Inc. uses its website, www.proventionbio.com , as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D.

Landos Biopharma Announces Appointment of Fabio Cataldi, MD, as Chief Medical Officer

Retrieved on: 
Tuesday, September 6, 2022

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Fabio Cataldi, MD, as the Companys Chief Medical Officer, effective September 5, 2022.

Key Points: 
  • NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Fabio Cataldi, MD, as the Companys Chief Medical Officer, effective September 5, 2022.
  • Dr. Cataldi joins Landos with more than twenty years of successful experience in the development and commercialization of innovative therapies.
  • Fabios appointment as Chief Medical Officer is an important step as we look to continue selectively growing our leadership team with the talent and expertise that we need to successfully advance our pipeline.
  • Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases.

Allsup Supports “Walk To End Lupus Now 2022” with LFA Heartland Chapter On Saturday, Sept. 10

Retrieved on: 
Wednesday, August 31, 2022

An estimated 16,000 new cases of lupus are diagnosed each year, according to the foundation.

Key Points: 
  • An estimated 16,000 new cases of lupus are diagnosed each year, according to the foundation.
  • To register for the walk, learn more or to make a donation, visit Walk to End Lupus Now 2022 - St. Louis - Lupus Foundation of America .
  • Learn more about the Lupus Foundation of America, Heartland Chapter at lupus.org/heartland .
  • Learn more at Allsup.com and @Allsup or download a free PDF ofApplying for Social Security Disability Insurance: Getting It Right The First Time.

Lupus Foundation of America and Lupus Canada Award Grant for Critical Study Examining Platelet Biology as a Potential Lupus Treatment Pathway

Retrieved on: 
Wednesday, August 31, 2022

The findings from his study could uncover new pathways that impact lupus classification criteria and treatment.

Key Points: 
  • The findings from his study could uncover new pathways that impact lupus classification criteria and treatment.
  • "The Lupus Canada Catalyst Award from the Lupus Foundation of America and Lupus Canada is providing a unique opportunity to study this important area and utilize emerging new technologies to analyze these cells that hold potential promise for new lupus treatment pathways."
  • "Through our partnership with Lupus Canada we have been able to support even more researchers studying important new frontiers in lupus research," said Stevan W. Gibson, president and CEO, Lupus Foundation of America.
  • "The Lupus Canada Catalyst Grant, in partnership with the Lupus Foundation of America, illustrates our commitment to investing in Canadian researchers who are focused in the area of discoid or systematic lupus erythematosus (SLE).

Alpine Immune Sciences Announces R&D Day to Provide Clinical Updates on Wholly-Owned Programs ALPN-303 and Davoceticept

Retrieved on: 
Tuesday, August 30, 2022

Event registration will be available through the Alpine Immune Sciences website at https://ir.alpineimmunesciences.com/events .

Key Points: 
  • Event registration will be available through the Alpine Immune Sciences website at https://ir.alpineimmunesciences.com/events .
  • An archive of the presentation will be accessible after the event through the Alpine Immune Sciences website.
  • Alpine Immune Sciences is committed to leading a new wave of immune therapeutics.
  • Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development.